A D.C. university and Maryland biotech are teaming up to advance medical devices for cancer therapies — and Covid-19 — to the tune of $3.2 million.
George Washington University and Takoma Park life sciences and biomedical device company US Medical Innovations LLC have entered a corporate research agreement to develop what are called adaptive cold plasma devices. The partners are now studying that technology in gastrointestinal cancer “where the surgery is done and tumor is removed, and then residual cells or surgical margins are treated with the plasma to remove small lesions,” said Michael Keidar, a professor of engineering at GWU and mechanical engineer by training.
Read the full article at: www.bizjournals.com
The following two tabs change content below.
Chris Frew
President, CEO at Biobuzz Media & Workforce Genetics
Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.
Latest posts by Chris Frew (see all)
- Gyroscope Therapeutics, which has operations in King of Prussia, raises $148M - March 31, 2021
- TCR² Therapeutics Acquires Cell Therapy Manufacturing Facility & New VP of Technical Operations, Aaron Vernon - March 29, 2021
- Frederick Based Biotech Law Firm McBee Moore & Vanik IP, LLC Celebrates Five Years - February 18, 2021
- Heather Mudrick Joins Workforce Genetics to Lead Clinical Search Practice - February 12, 2021
- RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC - February 4, 2021
